细胞免疫治疗白血病研究进展  

Current Research Advance on Cellular Immunotherapy for Leukemia——Review

作　　者：田竑[1] 陈广华[1] 徐杨[1] 乔曼[1] 刘慧文[1] 吴德沛[1] 

机构地区：[1]苏州大学附属第一医院江苏省血液研究所,卫生部血栓与止血重点实验室,苏州215006

出　　处：《中国实验血液学杂志》2013年第5期1326-1330,共5页Journal of Experimental Hematology

基　　金：江苏省自然科学基金(编号:BK2010206);中国医师协会血液学分会科技计划项目(编号:20100145);江苏省高校优势学科建设工程资助项目,江苏省临床医学中心(编号:ZX201102);卫生部国家临床重点专科建设项目

摘　　要：尽管化疗能诱导恶性血液病缓解,但是缓解后存在复发风险且化疗毒性无法避免。研究人员一直致力于通过免疫手段清除肿瘤细胞。近年来,人们发现了许多白血病相关抗原(LAA)能被细胞毒性T细胞(CTL)所识别,同时具有HLA-I限制性。这些LAA包括WT1、PR-3、RHAMM、BCR-ABL和Aur-A等。在实验室研究基础上,目前开展的恶性血液病免疫治疗手段包括有肿瘤多肽疫苗、获得性T细胞治疗、NK细胞及DC-CIK治疗等。本文就细胞免疫治疗白血病研究进展作一综述。Despite the chemotherapy is successful in inducing remission of hematologic malignancy, this disease also has a high probability of relapse; besides, the toxicity of chemotherapy for these patients can not be avoided. Researchers have been attempting to eliminate tumor cells by immunotherapy. Recently, various leukemia-associated antigens （LAA） that are recognized by cytotoxic T cell （CTL） in the context of HLA class I molecules have been identified. These LAA include WT1, PR-3, RHAMM, BCR-ABL and Aur-A. On the basis of these findings, various clinical trials of immunotherapy for hematologic malignancy including tumor peptide vaccination, adoptive T cell therapy, NK cell therapy and dendritic cells-cytokine induced killer （DC-CIK） cell therapy are on going. In this review, the current status and future feasibility of cellular immunotherapy for leukemia are discussed.

关 键 词：白血病 细胞毒T细胞 肿瘤相关抗原 疫苗 免疫治疗 

分 类 号：R733.7[医药卫生—肿瘤] R457.2[医药卫生—临床医学]